Epivir is a brand-name antiviral medication that contains lamivudine as its sole active ingredient. Lamivudine belongs to the nucleoside reverse-transcriptase inhibitor (NRTI) class and is used to treat infections caused by retroviruses, most notably human immunodeficiency virus type 1 (HIV-1). In Hong Kong, Epivir is available only by prescription and is supplied as a 150 mg pill. The product is manufactured by GlaxoSmithKline and is approved by the Hong Kong Department of Health for use in adults and children with HIV infection.
Lamivudine interferes with the HIV life cycle by inhibiting reverse transcriptase, an enzyme the virus needs to convert its RNA genome into DNA. Once inside a cell, lamivudine is phosphorylated to its active triphosphate form, which then mimics the natural building block deoxycytidine-5′-triphosphate. When reverse transcriptase incorporates this mimic into the growing viral DNA chain, chain elongation stops, preventing the virus from integrating its genetic material into the host cell.
These indications are based on regulatory approvals from the Hong Kong Department of Health and align with international recommendations from the World Health Organization (WHO).
Patients should contact their healthcare provider if they experience new or worsening symptoms, such as persistent abdominal pain, breathlessness, or unexplained fatigue.
This article provides educational information about Epivir and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Epivir is designed to be part of a combination antiretroviral regimen. It can be co-administered with protease inhibitors, integrase inhibitors, or other NRTIs, but certain drug pairs (e.g., didanosine) increase the risk of toxicity and require clinical supervision.
Standard dosing is 150 mg once daily for most adults, regardless of weight. In cases of severe obesity or altered pharmacokinetics, clinicians may monitor plasma levels and adjust therapy if necessary.
Do not double the next dose. Take the next scheduled dose at the usual time and inform your healthcare provider, as prolonged gaps can allow viral rebound.
For patients with HIV alone, liver function tests are usually performed at baseline and then as clinically indicated. If you have concomitant hepatitis B, regular monitoring of ALT and AST is recommended.
Lamivudine may be continued during pregnancy when the benefits outweigh potential risks. It has been used in many pregnant women to reduce mother-to-child transmission of HIV, but the decision must be individualized by a specialist.
All lamivudine products contain the same active molecule and share identical efficacy. Differences may exist in inactive ingredients, tablet size, or manufacturer reputation, but therapeutic outcomes are equivalent when taken as prescribed.
Yes. Inconsistent adherence or sub-therapeutic dosing can lead to HIV mutations that confer resistance to lamivudine. Routine viral load monitoring helps detect resistance early.
Lamivudine alone has minimal impact on lipids. However, when combined with certain protease inhibitors, lipid abnormalities can arise, necessitating periodic lipid panel checks.
Yes, but keep the medication in its original packaging, carry a copy of the prescription, and be prepared to show it at customs. Some countries may require a doctor’s letter for controlled medicines.
Regulatory agencies consider bio-equivalent generics interchangeable with brand-name lamivudine. Switching should be done under medical supervision to ensure adherence and avoid confusion.
